

Request for Proposal

for Market Analysis of Tuberculosis (TB) Medicines in the Private Sector in Bangladesh

1. Background:

The USAID PQM plus (PQM+) program, implemented by the USP, in collaboration with the Directorate General of Drug Administration (DGDA) and National Tuberculosis Control Program (NTP) seeks to conduct a comprehensive market analysis of TB medicines within the private sector, focusing on production, import, sales volume, and quality management practices throughout the supply chain. The study aims to gain insights into the Good Pharmacy Practice (GPP), rational use of TB medicines at the retail level, estimate patient numbers based on sales data, and understand the policy and regulatory landscape involving the DGDA and the NTP.

The U.S. Pharmacopeial Convention (USP) is a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed, and consumed worldwide. USP's drug standards are enforceable in the United States by the Food and Drug Administration, and these standards are used in more than 140 countries.

2. Objectives:

- Assess the production and import volumes of TB medicines in Bangladesh.
- Analyze sales volumes and distribution practices in the private sector and private service providers.
- Evaluate the quality management practices at different levels of the supply chain including the Good Pharmacy Practices at the retail medicine shops.
- Understand the rational sales of first line TB medicines at the retail level.
- Analyze and estimate the number of patients purchasing TB medicines in the private sector.
- Explore policy and regulatory aspects involving DGDA and NTP.
- Develop a technical brief including policy recommendations based on the market analysis of TB medicines in Bangladesh private sector.

Click here to view details RFQ

<u>Proposal Submission:</u> Quotes are to be submitted via e-mail to, <u>Email: GPHBANGLADESHRECRU ITMENT@USP.ORG</u> with copy to <u>zillur.rahman@usp.org</u> and subject line "Market Analysis of Tuberculosis (TB) Medicines in the Private Sector" by Saturday May 4, 2024.